“…Sixty-eight studies were used to calculate adverse events and early removal rates, 10 45,79 For the EndoBarrier DJBS meta-analyses, 11 studies met inclusion criteria. [92][93][94][95][96][97][98][99][100][101][102] Of these, 9 reported adverse events and early removal rates, 92-97,99-101 3 reported %EWL at 12 months, 97,100,101 4 were RCTs that reported %EWL over a sham or control group at device removal, 92,94,95,100 9 reported changes in glycosylated hemoglobin (HgA 1c ), 92,93,[95][96][97][98][99][100]102 and 3 reported changes in HgA 1c over a sham or control group in RCTs. 93,95,100 %EWL at 12 months and mean difference in %EWL over a control group for primary EBTs Orbera IGB.…”